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Objectives: The newly-introduced glatiramer acetate (GA; COPAXONE®) 40 mg/
ml three times a week maintains the known efficacy and safety of GA 20 mg/ml 
once-daily but requires around 200 fewer injections per year (60% fewer) for people 
treated for relapsing forms of multiple sclerosis (MS). An economic model with a 
five-year time horizon estimated the financial impact to the Spanish healthcare 
system of reduced switching from GA-based regimens to more expensive newly-
introduced first-line disease modifying therapies (DMTs) and the second-line 
DMTs. MethOds: The eligible population was based on 2014 Spanish MS inci-
dence rates, with the proportion receiving DMTs calculated using market research 
data. Medication costs were based on known Spanish prices, while treatment initia-
tion, administration and monitoring costs were calculated from published Spanish 
sources and Summary of Product Characteristics documentation. Switching rates 
and future treatment patterns were based on manufacturer’s projections. Results: 
An estimated 5,084 people with MS received GA 20 mg/ml once-daily in Spain in 
2014 (12.1% of those receiving DMTs) and were assumed to switch to more expen-
sive newly-introduced first-line and second-line DMTs at an annual rate of 8%. 
Assuming these people received GA 40 mg/ml three times a week instead, and – due 
to requiring fewer injections – switched at an annual rate of 5%, total expenditure 
on DMTs and related costs was reduced by between € 5.9 million and € 7.2 million 
annually, with savings totalling € 32.8 million over five years: a 21% reduction in total 
expenditure related to DMTs included in the model, compared with GA 20 mg/ml 
once-daily. Savings were primarily driven by lower acquisition costs of GA compared 
with other DMTs, and also from lower initiation, administration and monitoring 
requirements. cOnclusiOns: Introducing GA 40 mg/ml three times a week may 
limit switching from GA to more expensive newly-introduced first- and second-line 
DMTs, potentially generating cost savings.
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Objectives: The objective of this study was to estimate the incremental budget 
impact (BI) of utilizing perampanel to treat partial-onset seizures (POS) in patients 
who are 12 years of age and older in Russia. MethOds: The incremental BI was 
estimated by comparing the cost of POS seizures with and without perampanel. 
Direct (drugs, healthcare provider visits, emergency room visits, hospitalizations) 
and indirect (overall work impairment) costs were included. The model was devel-
oped from a societal perspective. The time horizon is five years. Costs are reported 
in rubles (RUB). Results: An estimated 351,582 patients ages 12 years and older 
are treated for POS in Russia each year. Approximately 53% are refractory (experi-
encing persistent seizures despite current treatment). The market share uptake of 
perampanel in POS patients is estimated to be 3%, 5%, 10%, 15% and 20%, in years 1 
to 5, respectively. During these five years, the adoption of perampanel is projected to 
increase overall costs by 305M, 510M, 1,022M, 1,537M and 2,055M RUB, respectively. 
Due to seizure reductions with perampanel, 27% of the drug cost increase (5,428M 
RUB) over 5 years is offset by the lower utilization of direct medical resources (RUB 
-25M) and lower overall work impairment (RUB -1,450M), yielding an overall BI of 
2.5% over 5 years. cOnclusiOns: With a budget impact of only 2.5% over a period of 
5 years and demonstrated efficacy benefits in refractory POS patients (63% median 
reduction in secondarily generalized seizures and 13% seizure freedom rate), per-
ampanel should be considered a valuable treatment.
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Objectives: To project the number and costs of relapses and escalations to second-
line therapy over 2 years for subcutaneous (SC) interferon beta (IFNβ )-1a (Rebif®), 
intramuscular (IM) IFNβ -1a, IFNβ -1b, and glatiramer acetate (GA) in the treatment of 
first-line relapsing-remitting multiple sclerosis (RRMS) from the perspective of the 
UK National Health Service (NHS). MethOds: A four-state (initial therapy, alternate 
first-line therapy, second-line therapy [natalizumab], and discontinuation) Markov 
model was constructed to simulate a cohort of 1,000 newly-diagnosed RRMS patients. 
Transition probabilities were based on real-world persistence data from the NHS 
and a patient treatment flow study. Risk of relapse was linearly interpolated based 
on 2-year data from a Cochrane Review network meta-analysis. The cost of a relapse 
was sourced from the literature and inflated to 2014 GBP. Drug acquisition costs were 
sourced from the British National Formulary. Administration costs were sourced from 
a NICE costing template. One-way sensitivity analyses were performed to test the 
robustness of the model results. Results: Treatment with SC IFNβ -1a is projected 
to avoid 94, 7, and 7 additional relapses compared with IM IFNβ -1a, IFNβ -1b, and GA, 
respectively, resulting in cost savings of £279,460, £20,877, and £20,877 over 2 years 
in a hypothetical cohort of 1,000 newly-diagnosed RRMS patients. Treatment with 
corticosteroid pulse and plasmapheresis may help in acute attacks of NMO. Further 
well designed, adequately powered studies are required in this context.
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Objectives: The cost-effectiveness of CAH screening (a state-level policy) was 
assessed by Yoo and Grosse (2009) using national incidence (NATL). Incidence of 
rare genetic diseases often varies geographically, however, it is likely that some 
state variation is due to sampling error. This research assesses the extent of the 
sampling error explanation through a series of simulations. MethOds: We obtained 
actual state-level incidence (ASI) for the 50 US states plus DC for 2006. For the 
simulation we assumed that state equaled national incidence and constructed a 
Beta distribution with alpha parameter equaling predicted state cases, and Beta 
parameter equaling state births minus predicted cases. We then ran a Monte Carlo 
simulation of 1000 iterations and calculated the proportion of iterations for which 
the incidence draw was more extreme than the ASI (i.e. draw > ASI if ASI > NATL or 
draw < ASI if ASI < NATL). Small numbers of iterations more extreme than the ASI 
are consistent with the ASI not equaling NATL. Extreme was defined as less than 5% 
of draws in the simulation less than the ASI (if ASI< NATL) or greater than the ASI 
(if ASI > NATL). Results: ASI per 1000 births ranged from 0 to .343 (median, .038). 
There were 21 states with ASI < NATL (including 13 values of 0) and 25 states with 
ASI > NATL. Of the 46 states reporting ASI, 21 (47%) had an “extreme” ASI by our 
definition. cOnclusiOns: State incidence appears to be “extreme” vs the national 
average in a large number of states and, therefore, does not seem to be explained 
by sampling error alone. As a difference in incidence may affect cost-effectiveness, 
further exploration using ASIs instead of a national average may be beneficial for 
directing state-level screening policy.
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Objectives: The research is to analyze social demographic characteristics and 
health service use nature of Parkinson’s disease in Korea by using Korean National 
Health Insurance Claims dataset (HIRA-NPS 2013), which is one of the secondary 
sources of health and medical treatment provided by reimbursement authority, 
and to measure a direct medical costs of Parkinson’s disease. MethOds: Patients 
with primary or secondary disease code for Parkinson’s Disease according to Korean 
Standard Classification of Disease (KICD-10 code : G20) are selected from National 
Patients Sample Dataset. The characteristics of age, sex, length of stay for inpatients, 
the number of outpatient visit and medical cost were analyzed based on the patient 
dataset extracted. SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was used for statistical 
analysis. Results: The number of patients with Parkinson’s disease for the analysis 
was 4,137, and that of claims cases for 12 months was 34,259. The average age of 
the patients was 71.6 years old and the female patients composed 60.11%, which 
was about 1.5 times that of the male patients. The prevalence rate of Parkinson’s 
disease per 1,000 populations was 3.54 in 2013. Based on 1-year claims dataset, 
outpatient visit days were 9.83 and inpatient hospitalization days were 25.3. The 
annual direct medical costs were USD 487 for an outpatient and USD 10,429 for an 
inpatient. cOnclusiOns: As the result, the Parkinson’s disease is the economic 
burden in aging society in Korea. The limitation that the sample data used for 
the research is smaller than the raw data should be considered. Therefore further 
analysis on Parkinson’s disease in aging society is needed.
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Objectives: To estimate the prevalence of status epilepticus (SE), refractory status 
epilepticus (RSE), and super-refractory status epilepticus (SRSE) in five major European 
Union (5EU) markets (France, Germany, Italy, Spain, and the United Kingdom) using 
an incidence-survival model. MethOds: Yearly survival data for each SE etiology 
(acute symptomatic, progressive symptomatic, remote symptomatic, and idiopathic/
cryptogenic) were extracted from published research. Incident cases were calculated 
for each etiology beginning with 1995, based on market-specific published rates. 
Applying the survival proportions and incidence estimates to the model for each 
etiology, we calculated an overall estimate of the prevalence of SE. RSE and SRSE 
prevalent cases were assessed as proportions of the total number of prevalent SE 
cases using published values. Results: We estimated the prevalence of SE to be 
18.4 cases per 10,000 population in the 5EU, resulting in 590,264 cases in 2015 and 
increasing to 603,951 in 2024. The calculated prevalence ranged from 17.2 cases per 
10,000 (Germany) to 19.7 cases per 10,000 (Italy). The prevalence of RSE in the 5EU was 
4.5 per 10,000, resulting in 145,205 cases in 2015, increasing to 148,572 in 2024. SRSE 
prevalence in the 5EU was 1.8 per 10,000, resulting in 59,027 cases in 2015, increas-
ing to 60,395 in 2024. cOnclusiOns: To our knowledge, this is the first attempt to 
calculate the prevalence of SE and its subtypes for all ages in Europe. Estimating the 
prevalence of SE, RSE, and SRSE using population-based epidemiological methods is 
challenging because of the variability of SE disease definitions and the unpredictable 
nature of mortality due to SE. Our incidence-survival model provides an alternative 
and effective method to assess the prevalent population. Considering the high costs 
associated with treatment and hospitalization of SE, RSE, and SRSE patients, these 
estimates are necessary to quantify the burden of disease in Europe.
